Zoetis Reports Q3 2026 Results with Mixed Performance Amid U.S. Companion Animal Headwinds
Zoetis (ZTS) reported third-quarter 2026 revenue of $2.4 billion, representing a 1% organic decline driven by flat volumes and price decreases. While the international segment saw 4% organic growth supported by livestock and parasiticides, the U.S. companion animal market faced significant challenges. Specifically, dermatology sales fell 16% globally due to new competition and pricing actions, while U.S. clinic visits declined as rising veterinary costs pressured pet owner spending. Despite these headwinds, Zoetis maintained profitability with adjusted diluted EPS of $1.75, a 1% organic increase aided by share repurchases. The company provided narrowed full-year revenue guidance of $9.22 billion to $9.32 billion, projecting an organic decline of 1% to 2%. Management highlighted strong performance in the international livestock sector and diagnostics, even as they navigate increased cost-of-care concerns among U.S. consumers.
Tickers: $ZTS
Topics: Companion animal market headwinds EPS growth Livestock segment performance Revenue decline